- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00348998
Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Pilot Phase II Trial of Bevacizumab in Combination With Hormonal and Radiotherapy in Patients With High-Risk Prostate Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Androgens can cause the growth of prostate cancer cells. Drugs, such as goserelin and bicalutamide, may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells. Bevacizumab may also make tumor cells more sensitive to radiation therapy. Giving bevacizumab together with hormone therapy and radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving bevacizumab together with hormone therapy and radiation therapy works in treating patients with high-risk locally advanced prostate cancer.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
OBJECTIVES:
- Determine the safety and efficacy of giving bevacizumab together with hormonal therapy and radiotherapy in patients with high-risk locally advanced prostate cancer.
OUTLINE: This is an open-label, pilot study.
Beginning in week 1, patients receive goserelin subcutaneously once every 3 months for 2 years. Patients also receive oral bicalutamide once daily and bevacizumab IV over 30- to 90-minutes once every 2 weeks in weeks 1-16 and undergo radiotherapy 5 days a week in weeks 9-16. After completion of radiotherapy, patients receive a higher dose of bevacizumab once every 3 weeks in weeks 17-28.
After completion of study treatment, patients are evaluated at 30 days.
PROJECTED ACCRUAL: A total of 18 patients will be accrued for this study.
Studietype
Registrering (Forventet)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Washington
-
Seattle, Washington, Forente stater, 98101
- Benaroya Research Institute at Virginia Mason Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically confirmed adenocarcinoma of the prostate
High-risk, locally advanced disease (T2b-T4 disease), meeting 1 of the following criteria:
- Gleason score 8-10
Prostate-specific antigen > 20 ng/dL AND Gleason score 7
- T2a disease allowed provided ≥ 5 biopsies contain Gleason score 4 +3 cancer (minimum of 10 biopsies total required)
- No evidence of metastatic disease within the past 60 days by physical examination, chest x-ray, bone scan, and CT scan of abdomen and pelvis
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Hemoglobin > 8 g/dL
- Absolute granulocyte count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- Creatinine ≤ 1.5 times ULN
- Blood pressure ≤ 150/100 mm Hg
No cardiovascular disease, including any of the following:
- Unstable angina
- New York Heart Association class II-IV congestive heart failure
- History of myocardial infarction within the past 6 months
- History of stroke within the past 6 months
PRIOR CONCURRENT THERAPY:
- At least 4 weeks since prior major surgery
- No prior hormonal therapy (except finasteride for obstructive voiding symptoms) for prostate cancer
- No prior or concurrent chemotherapy, biologic therapy, or radiotherapy for prostate cancer
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
---|
Sikkerhet
|
Effektivitet
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studiestol: Jacqueline Vuky, MD, Virginia Mason Hospital/Medical Center
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Neoplasmer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Genitale neoplasmer, hanner
- Prostata sykdommer
- Prostatiske neoplasmer
- Fysiologiske effekter av legemidler
- Antineoplastiske midler
- Hormoner, hormonsubstitutter og hormonantagonister
- Antineoplastiske midler, hormonelle
- Antineoplastiske midler, immunologiske
- Angiogenese-hemmere
- Angiogenesemodulerende midler
- Vekststoffer
- Veksthemmere
- Hormonantagonister
- Androgenantagonister
- Goserelin
- Bevacizumab
- Bicalutamid
Andre studie-ID-numre
- CDR0000480370
- BRIVMRC-3031500
- GENENTECH-AVF3549s
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på goserelinacetat
-
CMX ResearchPeptigroupe Inc.FullførtProstatakreftCanada, Georgia
-
Wendell Yap, MDUniversity of Kansas Medical CenterIkke lenger tilgjengeligProstatakreftForente stater
-
Karolinska InstitutetFullført
-
Daniel VaenaFullførtProstatakreft | Kastratresistent prostatakreftForente stater
-
University of Alabama at BirminghamHar ikke rekruttert ennå
-
University of PennsylvaniaAvsluttetMild kognitiv sviktForente stater
-
Phoenix Molecular ImagingFullførtProstatakreftForente stater
-
Cancer Research AntwerpJanssen PharmaceuticaRekruttering
-
University of Michigan Rogel Cancer CenterJohns Hopkins University; Washington University School of Medicine; Northwestern... og andre samarbeidspartnereFullførtProstatakreftForente stater
-
Uppsala UniversityAvsluttetEffekter av restriktiv væskestrategi på postoperative pasienter med oligurisk bukspyttkjertelkirurgiPostoperative komplikasjoner | Væsketerapi | Væskeoverbelastning | Pankreas sykdom | Postoperativ periodeSverige